NoticeThis is an independent non-profit initiative. We are not affiliated with the European Medicines Agency (EMA) or the official CTIS system. For the official EU Clinical Trials Information System, visit:
EMA Registry →
This is a prospective, French, multicenter, open-label, design, stratified on the immunophenotypic
characterization (B- or T- lineage) and the patient risk group, that aims at evaluating the efficacy and the
tolerance of different schedules of pegaspargase in patients from 12 months to less than 18 years newly
diagnosed with standard/medium-risk ALL
1 total trials
Filter these 1 trials by phase, country, sponsor and more.